表紙
市場調查報告書
商品編碼
1028765

護理點的分子診斷市場:應用、技術、位置、產品、國家:COVID-19 的 PoC 突然發生,執行指南和定制(2021-2025)

Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With COVID-19 PoC Breakout and Executive Guides and Customization 2021 - 2025

出版日期: | 出版商: Howe Sound Research | 英文 533 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

COVID 大流行預示著床旁診斷新世界的到來。傳染病的診斷已經改變,並將繼續改變。

護理點測試正在市場上展示。市場進入者報告了兩位數的增長。它有助於降低成本、改善治療效果並對抗抗菌素耐藥性。

這份報告調查了 Point of Care 的分子診斷市場,並提供了市場概況以及應用、技術、位置、產品、國家和進入市場的公司概況的趨勢。

目錄

第 1 章市場指南

  • Point of Care 分子診斷-戰略形勢分析
  • COVID-19
  • 高管、營銷、銷售和業務發展人員指南
  • 管理顧問和投資顧問指南

第 2 章市場的介紹和定義

  • 什麼是 Point of Care 的分子診斷?
  • 診斷革命
  • 市場定義
    • 收入
  • 調查方法
    • 作者
    • 來源
  • 前景:醫療保健、IVD 行業和 COVID-19 大流行
    • 全球醫療保健支出
    • 診斷費用
    • 保險對診斷的重要作用

第 3 章傳染病-按疾病分類的市場分析

  • HIV-人類免疫缺陷病毒 (AIDS)
    • 病毒學
    • 診斷
    • 檢驗
    • 市場機會分析
  • HBV-B 型肝炎
    • 病毒學
    • 機制
    • 診斷
    • 市場機會分析
  • HCV-C 型肝炎
    • 分類方法
    • 結構
    • 分子生物學
    • 複製
    • 基因型
    • 市場機會分析
  • HPV-人乳頭瘤病毒
    • 病毒學
    • 診斷
    • 市場機會分析
  • 流感
    • 病毒學
    • 檢驗
    • 市場機會分析
  • CTGC-衣原體/淋病
    • 淋病
    • 衣原體
    • 檢驗
    • 市場機會分析
  • 結核病
    • 分枝桿菌
    • 診斷
    • 流行病學
    • 分子診斷測試
    • 市場機會分析
  • MRSA-耐甲氧西林金黃色葡萄球菌
    • 診斷
    • FDA 批准的分子檢測
    • 市場機會分析
  • VRE-萬古黴素耐藥腸球菌
    • FDA 批准的 VRE 分子診斷測試
    • 市場機會分析
  • 血液篩查
    • 採集和檢查
    • FDA 批准的多重檢測
    • 市場機會分析
  • COVID-19
    • 體徵和症狀
    • 感染
    • 診斷
    • 預防
    • 管理
    • 預後
  • 流行病診斷
    • 風險管理-激發和傳播
    • 診斷技術-基於核酸
    • 診斷技術-免疫測定和血清學
    • 啟動時間和準備問題
    • 多重在大流行管理中的作用未被認識到

第 4 章行業概況

  • 充滿活力的市場參與者
    • 學術研究室
    • 診斷測試開發人員
    • 儀器供應商
    • 分銷商和試劑供應商
    • 獨立實驗室
    • 公共國家/地區研究所
    • 醫院實驗室
    • 為從業者提供的實驗室和診所
    • 審計機構
    • 認證機構
  • 臨床檢測細分市場
    • 傳統的市場細分
    • 實驗室重點和細分
  • 產業結構
    • 醫院檢查分享
    • 規模經濟
    • 從業者實驗室
    • 醫生和 POCT

第 5 章主要 MDx 公司簡介

  • Abacus Diagnostica
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Aus Diagnostics
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Binx Health
  • Biocartis
  • bioM?rieux Diagnostics
  • Bio-Rad Laboratories, Inc
  • Bosch Healthcare Solutions GmbH
  • Cepheid(now Danaher)
  • Chembio
  • Co Diagnostics
  • Credo Diagnostics Biomedical
  • Cue Health
  • Curetis N.V./Curetis GmbH
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin S.p.A
  • Eiken Chemical
  • Enzo Life Sciences, Inc
  • Eurofins Scientific
  • Fluxergy
  • Fulgent Genetics
  • Fusion Genomics
  • Genedrive
  • Genetic Signatures
  • GenMark Dx
  • Grifols
  • Hibergene Diagnostics
  • Hologic
  • Illumina
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexagene
  • LightDeck Diagnostics
  • Luminex Corp
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Maxim Biomedical
  • Meridian Bioscience
  • Mesa Biotech
  • Millipore Sigma
  • Mindray
  • Mobidiag
  • Nanomix
  • Operon
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Primerdesign
  • Prominex
  • Qiagen Gmbh
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Siemens Healthineers
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Thermo Fisher Scientific Inc
  • Veramarx
  • Veredus Laboratories
  • Vir
  • XCR Diagnostics

第 6 章市場趨勢

  • 生長促進因素
    • 創造新市場的新基因型
    • 人口老齡化有益於所有診斷
    • 推動傳染病分子診斷髮展的世界發展
    • Point of Care-為什麼中心化正在失去動力
    • 自我檢查
    • 需要速度
    • COVID 大流行
  • 生長抑制因素
    • 低成本
    • 減少傳染病
    • 健康危害
    • 通過經濟增長提高生活水平
  • 儀器儀表和自動化
    • 設備是市場份額的關鍵
    • 收縮器
    • Multiplex、Point of Care 和 Speed Factor
  • 診斷技術的發展
    • 膿毒症檢測市場-新方向
    • POCT/自我反省作為破壞力
    • 遺傳學——對所有已知感染的一種測試
    • 抗生素抗性基因-簡化診斷

第 7 章傳染病的分子診斷-最新進展

第 8 章全球護理點分子診斷市場

  • 按國家/地區分列的世界市場概覽
    • Table-World Markets by Country
    • 按國家/地區繪製世界市場
  • 按應用劃分的全球市場-概覽
    • 表-世界市場-按國別
    • 圖表-世界市場-按使用-標□□準/最後一年比較
    • 圖表-世界市場-按使用基年
    • 圖表-世界市場-按用途-年末
    • 圖表-世界市場-按使用-份額按年
    • 圖表世界市場-按用途-細分市場增長
  • 世界市場-按技術-概覽
    • 表-世界市場-按技術
    • 圖表-世界市場-按技術-標準/最後一年比較
    • 圖表-世界市場-按技術-基礎年
    • 圖表-世界市場-按技術-年末
    • 圖表-世界市場-按技術-年份額
    • 圖表-世界市場-按技術-細分市場增長
  • 世界市場-按位置-概覽
    • 表-世界市場-按地點
    • 圖表-世界市場-按地點-標準/最後一年比較
    • 圖表-世界市場-按位置-基準年
    • 圖表-世界市場-按地點-年末
    • 圖表-世界市場-按位置-按年份額
    • 圖表-世界市場-按位置-細分市場增長
  • 按產品概覽劃分的全球市場
    • 表-世界市場-按產品
    • 圖表-世界市場-按產品-標準/去年比較
    • 圖表-世界市場-按產品-基準年
    • 圖表-世界市場-按產品-年末
    • 圖表-世界市場-按產品-年份額
    • 按產品細分市場增長圖表

第 9 章全球護理點中的分子診斷市場:按應用

  • COVID-19
  • 呼吸道感染
  • 胃腸道感染
  • 性傳播疾病
  • 其他

第 10 章全球護理點中的分子診斷市場:通過技術

  • PCR
  • NGS/探針
  • 其他

第 11 章全球護理點中的分子診斷市場:按位置

  • 醫院
  • 診所或醫生
  • 老人設施
  • 其他

第 12 章全球護理點中的分子診斷市場:副產品

  • 設備
  • 墨盒
  • 其他

第 13 章附錄

  • 美國醫療保險系統:2021 年實驗室費用表
目錄

OVERVIEW:

The COVID pandemic is ushering in a new world of point of care diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Point of Care testing move into the Physician's Office or even the Home? How much COVID-19 testing is being done at the Point of Care?

Point of Care testing is proving itself in the market. Players are reporting double digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out to 2025.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Molecular Diagnostics at the Point of Care - Strategic Situation Analysis and Impact of
  • COVID-19
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 What are Molecular Diagnostics at the Point of Care?
  • 2.2 The Diagnostics Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenues
  • 2.4 Methodology
    • 2.4.1 Authors
    • 2.4.2 Sources
  • 2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 The Infectious Diseases - Market Analysis by Disease

  • 3.1 HIV - Human Immunodeficiency Virus (AIDS)
    • 3.1.1 Virology
      • 3.1.1.1 Classification
      • 3.1.1.2 Structure and genome
      • 3.1.1.3 Tropism
      • 3.1.1.4 Replication cycle
      • 3.1.1.5 Genetic variability
    • 3.1.2 Diagnosis
    • 3.1.3 Testing
      • 3.1.3.1 Antibody tests
      • 3.1.3.2 Point of Care Tests (POCT)
      • 3.1.3.3 Antigen Tests
      • 3.1.3.4 Nucleic acid-based tests (NAT)
      • 3.1.3.5 Other tests used in HIV treatment
    • 3.1.4 Market Opportunity Analysis
  • 3.2 HBV - Hepatitis B
    • 3.2.1 Virology
      • 3.2.1.1 Genome
      • 3.2.1.2 Pathogenesis
      • 3.2.1.3 Hepatitis B virus replication
      • 3.2.1.4 Serotypes and genotypes
    • 3.2.2 Mechanisms
    • 3.2.3 Diagnosis
    • 3.2.4 Market Opportunity Analysis
  • 3.3 HCV - Hepatitis C
    • 3.3.1 Taxonomy
    • 3.3.2 Structure
      • 3.3.2.1 Genome
    • 3.3.3 Molecular biology
    • 3.3.4 Replication
    • 3.3.5 Genotypes
      • 3.3.5.1 Clinical importance
    • 3.3.6 Market Opportunity Analysis
  • 3.4 HPV - Human papillomavirus
    • 3.4.1 Virology
      • 3.4.1.1 E6/E7 proteins
      • 3.4.1.2 Role in cancer
      • 3.4.1.3 E2 research
      • 3.4.1.4 Latency period
      • 3.4.1.5 Clearance
    • 3.4.2 Diagnosis
      • 3.4.2.1 Cervical testing
      • 3.4.2.2 Oral testing
      • 3.4.2.3 Testing men
      • 3.4.2.4 Other testing
    • 3.4.3 Market Opportunity Analysis
  • 3.5 Influenza
    • 3.5.1 Virology
      • 3.5.1.1 Types of virus
      • 3.5.1.2 Influenzavirus A
      • 3.5.1.3 Influenzavirus B
      • 3.5.1.4 Influenzavirus C
      • 3.5.1.5 Structure, properties, and subtype nomenclature
      • 3.5.1.6 Replication
    • 3.5.2 Testing
      • 3.5.2.1 Advantages/Disadvantages of Molecular Assays
    • 3.5.3 Market Opportunity Analysis
  • 3.6 CTGC - Chlamydia/Gonorhea
    • 3.6.1 Gonorrhea
      • 3.6.1.1 Diagnosis
      • 3.6.1.2 Screening
    • 3.6.2 Chlamydia
      • 3.6.2.1 Diagnosis
      • 3.6.2.2 Screening
    • 3.6.3 Testing
      • 3.6.3.1 Nucleic acid amplification tests (NAATs)
      • 3.6.3.2 Performance of NAAT Tests
    • 3.6.4 Market Opportunity Analysis
  • 3.7 Tuberculosis
    • 3.7.1 Mycobacteria
    • 3.7.2 Diagnosis
      • 3.7.2.1 Active tuberculosis
      • 3.7.2.2 Latent tuberculosis
    • 3.7.3 Epidemiology
    • 3.7.4 Molecular Diagnostic Tests
    • 3.7.5 Market Opportunity Analysis
  • 3.8 MRSA - Methicillin-resistant Staphylococcus aureus
    • 3.8.1 Diagnosis
    • 3.8.2 FDA Approved Molecular Tests
    • 3.8.3 Market Opportunity Analysis
  • 3.9 VRE - Vancomycin-resistant Enterococcus
    • 3.9.1 FDA Approved MDx Tests for VRE
    • 3.9.2 Market Opportunity Analysis
  • 3.10 Blood Screening
    • 3.10.1 Collection and Testing
    • 3.10.2 FDA Approved Multiplex Assays
    • 3.10.3 Market Opportunity Analysis
  • 3.11 COVID-19
    • 3.11.1 Signs and symptoms
    • 3.11.2 Transmission
    • 3.11.3 Diagnosis
    • 3.11.4 Prevention
    • 3.11.5 Management
    • 3.11.6 Prognosis
  • 3.12 Pandemic Diagnostics
    • 3.12.1 Risk Management - Spark and Spread
    • 3.12.2 Dx Technology - Nucleic Acid Based
    • 3.12.3 Dx Technology - Immunoassay & Serology
    • 3.12.4 Time to Market and Preparedness Issues
    • 3.12.5 Unrecognized Role of Multiplex in Pandemic Mangement

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Instrumentation Supplier
    • 4.1.4 Distributor and Reagent Supplier
    • 4.1.5 Independent Testing Lab
    • 4.1.6 Public National/regional lab
    • 4.1.7 Hospital lab
    • 4.1.8 Physician Office Labs and Clinics
    • 4.1.9 Audit Body
    • 4.1.10 Certification Body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
      • 4.3.2.1 Hospital vs. Central Lab
    • 4.3.3 Physician Office Lab's
    • 4.3.4 Physician's and POCT

5 Profiles of Key MDx Companies

  • 5.1 Abacus Diagnostica
  • 5.2 Abbott Diagnostics
  • 5.3 Accelerate Diagnostics
  • 5.4 Ador Diagnostics
  • 5.5 Akonni Biosystems
  • 5.6 Alveo Technologies
  • 5.7 Applied BioCode
  • 5.8 Aus Diagnostics
  • 5.9 Beckman Coulter Diagnostics
  • 5.10 Becton, Dickinson and Company
  • 5.11 Binx Health
  • 5.12 Biocartis
  • 5.13 bioMérieux Diagnostics
  • 5.14 Bio-Rad Laboratories, Inc
  • 5.15 Bosch Healthcare Solutions GmbH
  • 5.16 Cepheid (now Danaher)
  • 5.17 Chembio
  • 5.18 Co Diagnostics
  • 5.19 Credo Diagnostics Biomedical
  • 5.20 Cue Health
  • 5.21 Curetis N.V. / Curetis GmbH
  • 5.22 Diagenode Diagnostics
  • 5.23 Diascopic
  • 5.24 Diasorin S.p.A
  • 5.25 Eiken Chemical
  • 5.26 Enzo Life Sciences, Inc
  • 5.27 Eurofins Scientific
  • 5.28 Fluxergy
  • 5.29 Fulgent Genetics
  • 5.30 Fusion Genomics
  • 5.31 Genedrive
  • 5.32 Genetic Signatures
  • 5.33 GenMark Dx
  • 5.34 Grifols
  • 5.35 Hibergene Diagnostics
  • 5.36 Hologic
  • 5.37 Illumina
  • 5.38 Immunexpress
  • 5.39 Inflammatix
  • 5.40 Invetech
  • 5.41 Janssen Diagnostics
  • 5.42 Karius
  • 5.43 Lexagene
  • 5.44 LightDeck Diagnostics
  • 5.45 Luminex Corp
  • 5.46 Lumos Diagnostics
  • 5.47 Mammoth Biosciences
  • 5.48 Maxim Biomedical
  • 5.49 Meridian Bioscience
  • 5.50 Mesa Biotech
  • 5.51 Millipore Sigma
  • 5.52 Mindray
  • 5.53 Mobidiag
  • 5.54 Nanomix
  • 5.55 Operon
  • 5.56 Oxford Nanopore Technologies
  • 5.57 Panagene
  • 5.58 Perkin Elmer
  • 5.59 Primerdesign
  • 5.60 Prominex
  • 5.61 Qiagen Gmbh
  • 5.62 Quantumdx
  • 5.63 Quidel
  • 5.64 Roche Molecular Diagnostics
  • 5.65 Saw Diagnostics
  • 5.66 Seegene
  • 5.67 Siemens Healthineers
  • 5.68 Sona Nanotech
  • 5.69 SpeeDx
  • 5.70 T2 Biosystems
  • 5.71 Thermo Fisher Scientific Inc
  • 5.72 Veramarx
  • 5.73 Veredus Laboratories
  • 5.74 Vir
  • 5.75 XCR Diagnostics

6 Market Trends

  • 6.1 Factors Driving Growth
    • 6.1.1 New Genotypes Creating New Markets
    • 6.1.2 Aging Population a Boon for All Diagnostics
    • 6.1.3 Developing World Driving ID Dx Growth
    • 6.1.4 Point of Care - Why Centralization is Losing Steam
    • 6.1.5 Self Testing
    • 6.1.6 The Need for Speed
    • 6.1.7 The COVID Pandemic
  • 6.2 Factors Limiting Growth
    • 6.2.1 Lower Costs
    • 6.2.2 Infectious Disease is Declining
    • 6.2.3 Wellness Hurts
    • 6.2.4 Economic Growth improves Living Standards
  • 6.3 Instrumentation and Automation
    • 6.3.1 Instruments Key to Market Share
    • 6.3.2 The Shrinking Machine
    • 6.3.3 Multiplex, Point of Care and The Speed Factor
  • 6.4 Diagnostic Technology Development
    • 6.4.1 The Sepsis Testing Market - A New Direction?
    • 6.4.2 POCT/Self Testing as a Disruptive Force
    • 6.4.3 The Genetics Play - One Test for All Known Infections
    • 6.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

7 Molecular Dx - Infectious Disease Recent Developments

  • 7.1 Recent Developments - Importance and How to Use This Section
    • 7.1.1 Importance of These Developments
    • 7.1.2 How to Use This Section
  • 7.2 Home Test Company Prenetics to go Public
  • 7.3 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio
  • 7.4 Lucira Health Posts Revenue Growth on OTC C19 Test
  • 7.5 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
  • 7.6 Talis Biomedical Discusses Point-of-Care
  • 7.7 Roche to Acquire GenMark Diagnostics for $1.8B
  • 7.8 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
  • 7.9 Hologic to Acquire Mobidiag
  • 7.10 Lucira Health Focuses on User Friendly Approach to Home Testing
  • 7.11 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
  • 7.12 Fluidigm Plans 'Durable' Diagnostics, Clinical Business
  • 7.13 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
  • 7.14 Mammoth Biosciences Developing Pathogen Detection Tech
  • 7.15 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
  • 7.16 Scanogen Developing 90 Minute Infection Test
  • 7.17 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
  • 7.18 FDA Provides Self Testing SARS-CoV-2 EAU Guidance
  • 7.19 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
  • 7.20 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
  • 7.21 Qiagen Respiratory Panel with Coronavirus Receives CE Mark
  • 7.22 Lumos Diagnostics Closes $15M Series A Funding
  • 7.23 Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay
  • 7.24 New Genomic Tests Diagnose Deadly Infections Faster
  • 7.25 Biotia Raises $2.4M Seed Round
  • 7.26 STDs resurge in US
  • 7.27 Ares Genetics signs R&D agreement with leading global IVD corporation
  • 7.28 Cell-Free DNA Used for Infectious Disease Testing
  • 7.29 One BioMed Raises $5M

8 The Global Market for Molecular Diagnostics at the Point of Care

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Application - Overview
    • 8.2.1 Table - Global Market by Application
    • 8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Application - Base Year
    • 8.2.4 Chart - Global Market by Application - End Year
    • 8.2.5 Chart - Global Market by Application - Share by Year
    • 8.2.6 Chart - Global Market by Application - Segments Growth
  • 8.3 Global Market by Technology - Overview
    • 8.3.1 Table - Global Market by Technology
    • 8.3.2 Chart - Global Market by Technology - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Technology - Base Year
    • 8.3.4 Chart - Global Market by Technology - End Year
    • 8.3.5 Chart - Global Market by Technology - Share by Year
    • 8.3.6 Chart - Global Market by Technology - Segments Growth
  • 8.4 Global Market by Place - Overview
    • 8.4.1 Table - Global Market by Place
    • 8.4.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Place - Base Year
    • 8.4.4 Chart - Global Market by Place - End Year
    • 8.4.5 Chart - Global Market by Place - Share by Year
    • 8.4.6 Chart - Global Market by Place - Segments Growth
  • 8.5 Global Market by Product - Overview
    • 8.5.1 Table - Global Market by Product
    • 8.5.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 8.5.3 Chart - Global Market by Product - Base Year
    • 8.5.4 Chart - Global Market by Product - End Year
    • 8.5.5 Chart - Global Market by Product - Share by Year
    • 8.5.6 Chart - Global Market by Product - Segments Growth

9 Global MDx at the Point of Care Markets - By Application

  • 9.1 Covid - 19
    • 9.1.1 Table Covid - 19 - by Country
    • 9.1.2 Chart - Covid - 19 Growth
  • 9.2 Respiratory Infectious Disease
    • 9.2.1 Table Respiratory Infectious Disease - by Country
    • 9.2.2 Chart - Respiratory Infectious Disease Growth
  • 9.3 Gastrointestinal Infectious Disease
    • 9.3.1 Table Gastrointestinal Infectious Disease - by Country
    • 9.3.2 Chart - Gastrointestinal Infectious Disease Growth
  • 9.4 Sexually Transmitted Disease
    • 9.4.1 Table Sexually Transmitted Disease - by Country
    • 9.4.2 Chart - Sexually Transmitted Disease Growth
  • 9.5 Other Application
    • 9.5.1 Table Other Application - by Country
    • 9.5.2 Chart - Other Application Growth

10 Global MDx Markets at the Point of Care - by Technology

  • 10.1 PCR
    • 10.1.1 Table PCR - by Country
    • 10.1.2 Chart - PCR Growth
  • 10.2 NGS/Probe
    • 10.2.1 Table NGS/Probe - by Country
    • 10.2.2 Chart - NGS/Probe Growth
  • 10.3 Other Technology
    • 10.3.1 Table Other Technology - by Country
    • 10.3.2 Chart - Other Technology Growth

11 Global MDx at the Point of Care Markets - by Place

  • 11.1 Hospital Point of Care
    • 11.1.1 Table Hospital Point of Care - by Country
    • 11.1.2 Chart - Hospital Point of Care Growth
  • 11.2 Clinic or Physician Office Lab
    • 11.2.1 Table Clinic or Physician Office Lab - by Country
    • 11.2.2 Chart - Clinic or Physician Office Lab Growth
  • 11.3 Seniors Facility
    • 11.3.1 Table Seniors Facility - by Country
    • 11.3.2 Chart - Seniors Facility Growth
  • 11.4 Other Place
    • 11.4.1 Table Other Place- by Country
    • 11.4.2 Chart - Other Place Growth

12 Global MDx at the Point of Care Markets - by Product

  • 12.1 Instrument
    • 12.1.1 Table Instrument - by Country
    • 12.1.2 Chart - Instrument Growth
  • 12.2 Cartridge
    • 12.2.1 Table Cartridge - by Country
    • 12.2.2 Chart - Cartridge Growth
  • 12.3 Other Product
    • 12.3.1 Table Other Product - by Country
    • 12.3.2 Chart - Other Product Growth

13 Appendices

  • 13.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule

Table of Tables

  • Table 1 Classification of HIV Species
  • Table 2 HIV Tests - CMS Codes & Prices
  • Table 3 Current HIV Molecular Tests and Instruments Used
  • Table 4 HBV Tests - CMS Codes & Prices
  • Table 5 HCV Tests - CMS Codes & Prices
  • Table 6 HPV Clearance Rates
  • Table 7 HPV Tests - CMS Codes & Prices
  • Table 8 HPV Tests, Technology, Types
  • Table 9 Types of Influenza Tests
  • Table 10 Influenza Tests - CMS Codes & Prices
  • Table 11 FDA Cleared Molecular Assays for Influenza
  • Table 12 FDA Cleared NAAT CTGC Tests
  • Table 13 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 14 CTGC Tests - CMS Codes & Prices
  • Table 15 FDA Approved MDx Tests for Tuberculosis
  • Table 16 Tuberculosis Tests - CMS Codes & Prices
  • Table 17 FDA Approved Tests for MRSA
  • Table 18 MRSA Tests - CMS Codes & Prices
  • Table 19 FDA Approved Tests for VRE
  • Table 20 VRE Tests - CMS Codes & Prices
  • Table 21 FDA Approved Multiplex Assays
  • Table 22 Characteristics of Coronavirus Pandemic Infections
  • Table 23 COVID-19 Symptoms
  • Table 24 Market Players by Type
  • Table 25 Clinical Laboratory Departments and Segments
  • Table 26 Laboratory Management Focus - Different Approaches
  • Table 27 Key Segmentation Variables Going Forward
  • Table 28 Five Factors Driving Growth
  • Table 29 Four Factors Limiting Growth
  • Table 30 Key Diagnostic Laboratory Technology Trends
  • Table 31 - Global Market by Region
  • Table 32 Global Market by Application
  • Table 33 Global Market by Technology
  • Table 34 Global Market by Place
  • Table 35 Global Market by Product
  • Table 36 Covid - 19 by Country
  • Table 37 Respiratory Infectious Disease by Country
  • Table 38 Gastrointestinal Infectious Disease by Country
  • Table 39 Sexually Transmitted Disease by Country
  • Table 40 Other Application by Country
  • Table 41 PCR by Country
  • Table 42 NGS/Probe by Country
  • Table 43 Other Technology by Country
  • Table 44 Hospital Point of Care by Country
  • Table 45 Clinic or Physician Office Lab by Country
  • Table 46 Seniors Facility by Country
  • Table 47 Other Place by Country
  • Table 48 Instrument by Country
  • Table 49 Cartridge by Country
  • Table 50 Other Product by Country
  • Table 51 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Map - Global Healthcare Spending Per Capita
  • Figure 2 The Lab Test Pie - Wholesale vs. Retail
  • Figure 3 HIV Virion
  • Figure 4 Diagram of the HIV Replication Cycle
  • Figure 5 The Structure of the HBV Virus
  • Figure 6 Hepatitis B Replication
  • Figure 7 Structure of the HCV Virus
  • Figure 8 HCV Replication Cycle
  • Figure 9 Structure of the Influenza Virion
  • Figure 10 Influenza Replication
  • Figure 11 Scanning Electronmicrograph of Tuberculosis
  • Figure 12 Percentage of World Population Over 65
  • Figure 13 Chart Infectious Disease Decline
  • Figure 14 Global Market Shares Chart
  • Figure 15 Global Market by Application - Base vs. Final
  • Figure 16 Global Market by Application Base Year
  • Figure 17 Global Market by Application End Year
  • Figure 18 Application Share by Year
  • Figure 19 Application Segments Growth
  • Figure 20 Global Market by Technology - Base vs. Final
  • Figure 21 Global Market by Technology Base Year
  • Figure 22 Global Market by Technology End Year
  • Figure 23 Technology Share by Year
  • Figure 24 Technology Segments Growth
  • Figure 25 Global Market by Place - Base vs. Final
  • Figure 26 Global Market by Place Base Year
  • Figure 27 Global Market by Place End Year
  • Figure 28 Place Share by Year
  • Figure 29 Place Segments Growth
  • Figure 30 Global Market by Product - Base vs. Final
  • Figure 31 Global Market by Product Base Year
  • Figure 32 Global Market by Product End Year
  • Figure 33 Product Share by Year
  • Figure 34 Product Segments Growth
  • Figure 35 Covid - 19 Growth
  • Figure 36 Other Infectious Disease Diagnostics Growth
  • Figure 37 Gastrointestinal Infectious Disease Growth
  • Figure 38 Sexually Transmitted Disease Growth
  • Figure 39 Other Application Growth
  • Figure 40 PCR Growth
  • Figure 41 NGS/Probe Growth
  • Figure 42 Other Technology Growth
  • Figure 43 Hospital Point of Care Growth
  • Figure 44 Clinic or Physician Office Lab Growth
  • Figure 45 Seniors Facility Growth
  • Figure 46 Other Place Growth
  • Figure 47 Instrument Growth
  • Figure 48 Cartridge Growth
  • Figure 49 Other Product Growth